Search Result

Results for "

age-related

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Interleukin Related (1) AMPK (2) Antibiotic (4) Apoptosis (7) Autophagy (6) Bacterial (5) Bcl-2 Family (1) Biochemical Assay Reagents (1) Casein Kinase (1) CCR (2) Complement System (6) Dipeptidyl Peptidase (2) Estrogen Receptor/ERR (1) FGFR (2) Fungal (4) HSP (1) IKK (4) Isotope-Labeled Compounds (2) JNK (1) Keap1-Nrf2 (4) LPL Receptor (1) Mitochondrial Metabolism (1) Mitophagy (4) MyD88 (1) nAChR (1) NAMPT (1) NF-κB (1) Nuclear Factor of activated T Cells (NFAT) (1) Oxidative Phosphorylation (2) PDGFR (3) Phospholipase (3) Ser/Thr Protease (1) Sirtuin (5) Small Interfering RNA (siRNA) (2) Src (2) SRPK (2) VEGFR (13) YAP (2)
By Research Areas:	Cancer (16) Cardiovascular Disease (9) Infection (5) Inflammation/Immunology (11) Metabolic Disease (12) Neurological Disease (13)

By Targets:

Interleukin Related (1)

AMPK (2)

Antibiotic (4)

Apoptosis (7)

Autophagy (6)

Bacterial (5)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Casein Kinase (1)

CCR (2)

Complement System (6)

Dipeptidyl Peptidase (2)

Estrogen Receptor/ERR (1)

FGFR (2)

Fungal (4)

HSP (1)

IKK (4)

Isotope-Labeled Compounds (2)

JNK (1)

Keap1-Nrf2 (4)

LPL Receptor (1)

Mitochondrial Metabolism (1)

Mitophagy (4)

MyD88 (1)

nAChR (1)

NAMPT (1)

NF-κB (1)

Nuclear Factor of activated T Cells (NFAT) (1)

Oxidative Phosphorylation (2)

PDGFR (3)

Phospholipase (3)

Ser/Thr Protease (1)

Sirtuin (5)

Small Interfering RNA (siRNA) (2)

Src (2)

SRPK (2)

VEGFR (13)

YAP (2)

By Research Areas:

Cancer (16)

Cardiovascular Disease (9)

Infection (5)

Inflammation/Immunology (11)

Metabolic Disease (12)

Neurological Disease (13)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Interleukin Related Mas-related G-protein-coupled Receptor (MRGPR) Trk Receptor ROR NEKs Kallikrein Atg4 CGRP Receptor Atg8/LC3 Arp2/3 Complex ATM/ATR sFRP-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99629

Galegenimab FHTR 2163; RG 6147; RO 7171009	Ser/Thr Protease	Neurological Disease
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .

HY-P3204

POT-4 AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-136788A

ALK4290 dihydrochloride AKST4290 dihydrochloride	CCR	Inflammation/Immunology
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .

HY-136788

ALK4290 AKST4290	CCR	Neurological Disease Inflammation/Immunology
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .

HY-150069

UBX1325	Bcl-2 Family Apoptosis	Metabolic Disease
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-110195

Smurf1-IN-A01 1 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9951A

Ranibizumab (anti-VEGF) RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-16467

Squalamine lactate MSI-1256F	Bacterial	Infection Cardiovascular Disease Cancer
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

HY-162269

Nampt activator-5	NAMPT	Neurological Disease
Nampt activator-5 (compound C8) is a potent nicotinamide phosphoribosyltransferase (NAMPT) activator with a K_D value of 6.19 µM. Nampt activator-5 shows a cellular antisenescence effect. Nampt activator-5 promotes the production of NAD ⁺ in the brain and reduces the expression of age-related markers and secretory phenotypes. Nampt activator-5 has the potential for the research of age-related diseases .

HY-P99402

Rinucumab REGN 2176	PDGFR	Metabolic Disease
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .

HY-147108

Mitochondria degrader-1	Mitochondrial Metabolism	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease .

HY-116098

Anecortave AL-4940	Biochemical Assay Reagents	Cancer
Anecortave (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .

HY-15492

AG-13958 AG-013958	VEGFR	Cardiovascular Disease
AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-P10140

JNK-IN-15, Cell-Permeable	JNK	Cancer
JNK-IN-15, Cell-Permeable (JNK inhibitor III) is an inhibitor of JNK. JNK-IN-15, Cell-Permeable can used in study age-related neurodegenerative diseasev .

HY-132126

SPHINX	SRPK	Others
SPHINX is a selective SRPK1 inhibitor with an IC₅₀ value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD .

HY-147080

Avacincaptad pegol sodium ARC1905	Complement System	Others
Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).

HY-163403

VEGFR-2-IN-43	VEGFR	Cardiovascular Disease Cancer
VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC₅₀ of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .

HY-153484A

Bevasiranib sodium	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-153484

Bevasiranib	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-114653

SRPIN803	Casein Kinase SRPK	Cancer
SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC₅₀s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .

HY-N1485

Cycloastragenol 3 Publications Verification Astramembrangenin; Cyclosieversigenin
Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties .

HY-153183

Lp-PLA2-IN-12	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .

HY-B0146

Verteporfin Maximum Cited Publications 142 Publications Verification CL 318952	YAP Apoptosis Autophagy	Cancer
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-14892

Gemigliptin LC15-0444	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-14892A

Gemigliptin tartrate LC15-0444 tartrate	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-153560

Lp-PLA2-IN-14	Phospholipase	Neurological Disease
Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC₅₀ of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .

HY-B0146R

Verteporfin (Standard) CL 318952 (Standard)	YAP Apoptosis Autophagy	Cancer
Verteporfin (Standard) is the analytical standard of Verteporfin. This product is intended for research and analytical applications. Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-110291

A-971432	Others	Neurological Disease
A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC₅₀s of .362, >10, 0.006 µM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .

HY-142778

Lp-PLA2-IN-10	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .

HY-11053

S 24795

nAChR Neurological Disease

S 24795 is a partial agonist of α7 nAChR and improves mnemonic function in aged mice for the research of aging-related memory disturbances .

S 24795	nAChR	Neurological Disease
S 24795 is a partial agonist of α7 nAChR and improves mnemonic function in aged mice for the research of aging-related memory disturbances .

HY-156781

Sirtuin-1 inhibitor 1	Sirtuin	Metabolic Disease
Sirtuin-1 inhibitor 1 (Compound 8) is an inhibitor of Sirtuin-1 that plays important roles in obesity-induced diabetes and aging-related diseases .

HY-139464

Q134R	Nuclear Factor of activated T Cells (NFAT)	Neurological Disease
Q134R, a neuroprotective hydroxyquinoline derivative that suppresses nuclear factor of activated T cell (NFAT) signaling. Q134R can across blood-brain barrier. Q134R has the potential for Alzheimer's disease (AD) and aging-related disorders research .

HY-16561

Resveratrol 75+ Cited Publications trans-Resveratrol; SRT501	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Infection Inflammation/Immunology Cancer
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-16561R

Resveratrol (Standard) 75+ Cited Publications trans-Resveratrol (Standard); SRT501 (Standard)	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Infection Inflammation/Immunology Cancer
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-148370

IONIS-FB-LRx RG6299	Complement System	Others
IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .

HY-148370A

IONIS-FB-LRx sodium RG6299 sodium	Complement System	Others
IONIS-FB-LRx sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .

HY-161115

NR2E3 agonist 1	Others	Inflammation/Immunology
NR2E3 agonist 1 (Compound 11a) is a small molecule agonist of the photoreceptor-specific nuclear receptor (NR2E3) with an EC₅₀ value of less than 200 nM. NR2E3 agonist 1 can be used in retinitis pigmentosa research .

HY-16561S1

Resveratrol-13C6 trans-Resveratrol-¹³C₆; SRT501-¹³C₆	Isotope-Labeled Compounds IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Infection Inflammation/Immunology Cancer
Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S

Resveratrol-d4 trans-Resveratrol-d₄; SRT501-d₄	Isotope-Labeled Compounds IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Infection Inflammation/Immunology Cancer
Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-136093A

Lixumistat acetate IM156; HL156A; HL271 acetate	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model . Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

Cat. No.	Product Name	Target	Research Area

HY-P99629

Galegenimab FHTR 2163; RG 6147; RO 7171009	Ser/Thr Protease	Neurological Disease
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9951A

Ranibizumab (anti-VEGF) RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99402

Rinucumab REGN 2176	PDGFR	Metabolic Disease
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16467

Squalamine lactate MSI-1256F	Infection Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Animals Terpenoids Marine natural products Other marine organisms Disease Research Fields	Bacterial
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

HY-16561

Resveratrol 75+ Cited Publications trans-Resveratrol; SRT501	Structural Classification Classification of Application Fields Anti-aging Source classification Vitis vinifera cv. Zalema Plants Vitaceae Infection Microorganisms Functional Molecules Sunscreen Research of Health Products Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-16561R

Resveratrol (Standard) 75+ Cited Publications trans-Resveratrol (Standard); SRT501 (Standard)	Infection Functional Molecules Classification of Application Fields Sunscreen Anti-aging Source classification Research of Health Products Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

Cat. No.	Product Name	Chemical Structure

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S1

Resveratrol-13C6

Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

age-related

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products